
|Articles|September 15, 2002
Macugen research: Enrollment ends early in trials for wet AMD drug
New York-Eyetech Pharmaceuticals Inc. has completed enrollment in two phase III trials of Macugen, its treatment for wet age-related macular degeneration (AMD), and has received $54.2 million from investors for further development of the drug.
Advertisement
Newsletter
Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Pediatric and strabismus care: Evolving tools, emerging therapies
2
Transformative advances in vision research: It’s the science
3
Eli Lilly to acquire Adverum Biotechnologies
4
Q&A: James Chelnis discusses AAO 2025 presentation on aesthetic facial surgery
5



















































.png)


